EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
WEST PALM BEACH, FL. June 16, 2020 – EXUMA Biotech Corporation, a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, is pleased to announce that H. Michael Shepard, Ph.D., an acting advisor to the company’s HER2 program, has been appointed to the Scientific Advisory Board. Additionally, Steven […]
Let’s Get the CAR-T Started
“Cancer is effectively a unicellular perspective on immortality, which has broken the social contract,” he says. “So when we look at the ability of cellular therapies to assist in that immunologic process of being able to treat patients and help them from the perspective of aging, I think that cancer is something which is one […]
Chairman & CEO Greg Frost on the Empowered Patient podcast with Karen Jagoda
Dr. Gregory Frost, Chairman & CEO of EXUMA Biotechnology, shares his insights into the tremendous progress made in developing autologous CAR-T therapies, as well as the challenges that remain for cell therapies surrounding safety and accessibility with Karen Jagoda on the Empowered Patient Podcast. EXUMA’s own “rPOC” (meaning “rapid point of care”) platform has the […]
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
WEST PALM BEACH, FL. March 12, 2020 – EXUMA Biotech Corp. (formerly F1 Oncology), a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors, today announced a $19M Series B round of financing that includes new investments by MSD Partners and F1 BioVentures, as well as conversion of notes held by […]
EXUMA Biotechnology Expands Leadership Team with Appointment of Chief Medical Officer and Chief Financial Officer
SHANGHAI and WEST PALM BEACH, Fla., June 18, 2019 — EXUMA Biotechnology, a clinical-stage biotechnology company discovering and developing CAR-T products for solid tumors and affiliate of F1 Oncology, Inc., announced today the expansion of its leadership team with the appointment of Wendy Li, M.D. as Chief Medical Officer and James Samuels as Chief Financial […]
Shanghai Perhum Therapeutics Announces Preliminary Results Of Two First-in-Human Solid Tumor CAR-T Products
MAINZ, Germany, May 21, 2019 — EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human solid tumor CAR-T products in subjects with recurrent or refractory stage IV metastatic renal cell carcinoma (mRCC). The data, presented at the Association for Cancer Immunotherapy (CIMT) 2019 Annual Meeting, continues to support the feasibility, […]
Same Day Transduction and In Vivo Expansion of a Chimeric Antigen Receptor with a Synthetic Driver Construct for Adoptive Cellular Therapy
AACR 2019 Abstract #2327 Link to poster Key Messages: We demonstrate viral transfer feasibility in a point of care (POC) platform using an engineered lentiviral vector retargeted to CD3, which efficiently transduces freshly isolated resting human PBMCs in four hours POC modified cells successfully engraft and expand in vivo upon IV administration in mice The entire […]
A Novel Conditionally Active Biologics Approach to Minimize On-target Off-tumor Effects in Adoptive Immunotherapy
AACR 2019 Abstract #3189 Link to poster Key Messages: We describe a novel approach to minimize on-Target off-tumor effects in CAR-T cell therapy in solid tumor We developed CAB-CARs by exploiting the unique property of TME that is an acidic extracellular pH environment Our CAB-CAR-T cells display “AND logic gate” properties, requiring both antigen […]
CAB-CAR-T: The Prioritization of Cell Surface Protein Targets for Conditionally Active Biologics to Treat All Solid Tumors
AACR 2019 Abstract #5101 Link to poster Key Messages: With the advent of Chimeric Antigen Receptor (CAR) T cell therapy to treat cancer, a new category of targetable biomarkers has emerged that are associated with the surface of malignant cells and serve as targets for cytotoxic T cells By modeling target mRNA expression from […]
A High-Throughput Screening Strategy for the Identification of Novel Lymphoproliferative Elements
AACR Abstract #3523 Link to poster Key Messages: The current work describes a high-throughput method for screening lymphoproliferative elements in vivo in a lentivirus format for next generation CAR-T therapies By quantification of selectively enriched human PBMCs we can identify combinatorial elements that promote CAR-T cell expansion and survival in an in vivo mouse model Our platform is robust, and also able to identify previously published lymphoproliferative elements (such as MyD88) as well as new, potent combinations of elements that are both dependent or independent […]
